Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 8/20 | 0.73 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.73 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | QPCT | Q16769 | 1/20 | 0.73 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.73 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.73 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylimidazole SCHEMBL16236718 | 0.86 | TBXAS1 (0.80) | TBXAS1CYP11B1CYP19A1CYP11B2CYP1A2 | |
| Benzylimidazole SCHEMBL16700262 | 0.85 | CYP11B1 (0.69) | TBXAS1CYP11B1CYP19A1CYP11B2CYP1A2 | |
| Benzylimidazole SCHEMBL414 | 0.85 | CYP11B1 (1.00) | TBXAS1CYP11B1CYP19A1CYP11B2CYP1A2 | |
| SCHEMBL22063900 | 0.85 | CYP11B1 (1.00) | TBXAS1CYP11B1CYP19A1CYP11B2CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL8307090 | 0.84 | CYP11B1 (0.74) | TBXAS1CYP11B1CYP19A1CYP11B2CYP1A2 | |
| Benzylimidazole SCHEMBL411827 | 0.84 | CYP11B1 (0.96) | TBXAS1CYP11B1CYP19A1CYP11B2CYP1A2 | |
| Benzylimidazole SCHEMBL16237308 | 0.84 | CYP11B1 (0.96) | TBXAS1CYP11B1CYP19A1CYP11B2CYP1A2 | |
| Benzylimidazole SCHEMBL29239318 | 0.84 | CYP11B1 (0.96) | TBXAS1CYP11B1CYP19A1CYP11B2CYP1A2 | |
| Benzylimidazole SCHEMBL31453527 | 0.84 | CYP11B1 (0.96) | TBXAS1CYP11B1CYP19A1CYP11B2CYP1A2 | |
| Benzylimidazole SCHEMBL3786782 | 0.84 | CYP11B1 (0.96) | TBXAS1CYP11B1CYP19A1CYP11B2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3244987-B1 | SEPARATIONS WITH IONIC LIQUID SOLVENTS | CHEVRON PHILLIPS CHEMICAL CO LP (US) | 2022-06-22 | — | — | EP | claimed |
| EP-3244987-A1 | SEPARATIONS WITH IONIC LIQUID SOLVENTS | Chevron Phillips Chemical Company LP (US) | 2017-11-22 | — | — | EP | claimed |
| US-20150133711-A1 | Separations With Ionic Liquid Solvents | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2015-05-14 | — | — | US | claimed |
| EP-3244987-B1 | SEPARATIONS WITH IONIC LIQUID SOLVENTS | CHEVRON PHILLIPS CHEMICAL CO LP (US) | 2022-06-22 | — | — | EP | disclosed |
| US-10227274-B2 | Separations with ionic liquid solvents | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2019-03-12 | — | — | US | disclosed |
| EP-3244987-A1 | SEPARATIONS WITH IONIC LIQUID SOLVENTS | Chevron Phillips Chemical Company LP (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20150133711-A1 | Separations With Ionic Liquid Solvents | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2015-05-14 | — | — | US | disclosed |
| EP-1858909-B1 | SYNTHESIS OF OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2014-09-10 | — | — | EP | disclosed |
| EP-1828218-B1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2014-04-30 | — | — | EP | disclosed |
| US-20130281682-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20120322994-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120316328-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20110065909-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20100081802-A1 | Synthesis of Phosphitylated Compounds Using a Quaternary Heterocyclic Activator | GIRINDUS AG (DE) | 2010-04-01 | — | — | US | disclosed |
| EP-1828218-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | Girindus AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064039-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065909-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, CPSF1, CPSF6 | TBXAS1 454/4885CYP11B1 2759/4885CYP19A1 768/4885 |
| US-20100081802-A1 | Synthesis of Phosphitylated Compounds Using a Quaternary Heterocyclic Activator | ARAF, ATIC, PFKFB3 | TBXAS1 2582/4885CYP11B1 3876/4885CYP19A1 2889/4885 |
| US-20120316328-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | ARAF, ATIC, PFKFB3 | TBXAS1 2817/4885CYP11B1 4127/4885CYP19A1 3224/4885 |
| US-20120322994-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, CPSF1, CPSF6 | TBXAS1 454/4885CYP11B1 2759/4885CYP19A1 768/4885 |
| US-20130281682-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | ARAF, ATIC, HK2 | TBXAS1 2516/4885CYP11B1 4175/4885CYP19A1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.